
Last updated: 2026-09-08 21:17:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Revolution Medicines, Inc. (RVMD) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $207.31, with a market capitalisation of $45.01B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $39.73 to $224.31. This page covers its latest market performance, valuation, price trends and company information.
$45.01B | |
$208.07 | |
$224.31 | |
$14.08 | |
$210.02 | |
1.43M | |
2.31M | |
-- | |
$224.31 | |
$39.73 | |
-- | |
-- |
Revolution Medicines, Inc. (RVMD) is trading at $207.83 in after-hours trading as of 2026-09-08 21:15:00, down 1.04% ($2.19) from the regular-session close of $210.02.
After-hours trading shows how investors are pricing RVMD after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Revolution Medicines, Inc. (RVMD) moved from $221.15 to $207.31, representing a decline of 6.26% ($13.84).
The stock traded between $200.53 and $224.31 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.83 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.8%
RVMD is currently trading at $207.31, placing it 90.8% of the way from its 52-week low of $39.73 to its 52-week high of $224.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 883 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Revolution Medicines, Inc. (RVMD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.